Hikma PHarmaceuticals Plc annual rePort 2013 NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 6.
Profit for tHe year Profit for the year has been arrived at after charging crediting : 2013 2012 $m $m net foreign exchange gain losses 2 3 research and development costs see note 5 39 34 depreciation and impairment of property, plant and equipment 49 43 amortisation of intangible assets including software 18 16 impairment of investment 16 inventories: cost of inventories recognised as an expense 354 368 Write-down of inventories see note 5 47 19 staff costs see note 7 319 294 the groups auditors remuneration on a worldwide basis was as below: 2013 2012 $m $m audit of the companys annual accounts 0.3 0.3 audit of the companys subsidiaries pursuant to legislation 1.2 1.1 Total audit fees 1.5 1.4 audit-related services 0.2 0.1 Total audit and audit-related fees 1.7 1.5 tax compliance services 0.1 0.1 tax advisory services 0.1 0.3 other services 0.4 0.3 Total non-audit fees 0.6 0.7 Total fees 2.3 2.2 audit-related services relate to review procedures in respect of the interim financial information other services include transaction services related to corporate transactions a description of the work of the audit committee is set out in the audit committee report on pages 70 to 76 and includes an explanation ofhowauditor objectivity and independence is safeguarded when non-audit services are provided by the auditor.
7. staff costs the average monthly number of employees including executive Directors was: 2013 2012 number number production 3,942 3,668 sales and marketing 2,097 1,853 research and development 205 200 General and administrative 823 800 7,067 6,521 144
